simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res
Company profile
Ticker
SLP
Exchange
Website
CEO
Shawn M. OConnor
Employees
Location
Fiscal year end
Industry (SIC)
Former names
SIMULATIONS PLUS INC
SEC CIK
Corporate docs
Subsidiaries
Simulations Plus International, Inc. ...
IRS number
954595609
SLP stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
6 Mar 24
8-K
Regulation FD Disclosure
13 Feb 24
8-K
Departure of Directors or Certain Officers
12 Feb 24
10-Q
2024 Q1
Quarterly report
5 Jan 24
8-K
Simulations Plus Reports First Quarter Fiscal 2024 Financial Results
3 Jan 24
ARS
2023 FY
Annual report to shareholders
22 Dec 23
DEFA14A
Additional proxy soliciting materials
22 Dec 23
DEF 14A
Definitive proxy
22 Dec 23
8-K
Regulation FD Disclosure
17 Nov 23
8-K
Regulation FD Disclosure
14 Nov 23
Transcripts
SLP
Earnings call transcript
2024 Q1
3 Jan 24
SLP
Earnings call transcript
2023 Q4
25 Oct 23
SLP
Earnings call transcript
2023 Q3
6 Jul 23
SLP
Earnings call transcript
2023 Q2
5 Apr 23
SLP
Earnings call transcript
2023 Q2
5 Mar 23
SLP
Earnings call transcript
2023 Q1
4 Jan 23
SLP
Earnings call transcript
2022 Q4
27 Oct 22
SLP
Earnings call transcript
2022 Q3
6 Jul 22
SLP
Earnings call transcript
2022 Q2
7 Apr 22
SLP
Earnings call transcript
2022 Q1
7 Jan 22
Latest ownership filings
4
WALTER S WOLTOSZ
5 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Neuberger Berman Group LLC
12 Feb 24
4
WALTER S WOLTOSZ
5 Feb 24
4
John Kenneth Paglia
2 Feb 24
4
DANIEL L WEINER
2 Feb 24
4
WALTER S WOLTOSZ
2 Feb 24
4
Lisa LaVange
2 Feb 24
4
Sharlene Evans
2 Feb 24
SC 13G/A
BlackRock Inc.
23 Jan 24
Financial summary
Quarter (USD) | Nov 23 | Aug 23 | May 23 | Feb 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Aug 23 | Aug 22 | Aug 21 | Aug 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 39.79 mm | 39.79 mm | 39.79 mm | 39.79 mm | 39.79 mm | 39.79 mm |
Cash burn (monthly) | 5.91 mm | 800.25 k | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 23.43 mm | 3.17 mm | n/a | n/a | n/a | n/a |
Cash remaining | 16.36 mm | 36.62 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 2.8 | 45.8 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
75.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 166 |
Opened positions | 23 |
Closed positions | 12 |
Increased positions | 53 |
Reduced positions | 56 |
13F shares | Current |
---|---|
Total value | 620.60 bn |
Total shares | 15.06 mm |
Total puts | 10.30 k |
Total calls | 4.40 k |
Total put/call ratio | 2.3 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 2.49 mm | $103.95 bn |
Conestoga Capital Advisors | 2.01 mm | $83.73 bn |
Neuberger Berman | 1.34 mm | $55.68 bn |
Vanguard | 1.12 mm | $46.66 bn |
Ranger Investment Management | 918.63 k | $38.31 bn |
STT State Street | 576.05 k | $24.02 bn |
IVZ Invesco | 469.96 k | $19.60 bn |
AMP Ameriprise Financial | 391.80 k | $16.34 bn |
Geode Capital Management | 370.93 k | $15.47 bn |
FMR | 362.79 k | $15.13 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Woltosz Walter S | Common Stock | Sell | Dispose S | No | Yes | 41.72 | 2,400 | 100.13 k | 3,620,195 |
1 Mar 24 | Woltosz Walter S | Common Stock | Sell | Dispose S | No | Yes | 41.37 | 17,600 | 728.11 k | 3,622,595 |
1 Feb 24 | Paglia John Kenneth | Common Stock | Grant | Acquire A | No | No | 0 | 792 | 0.00 | 2,889 |
4 Jan 24 | Paglia John Kenneth | Common Stock | Sell | Dispose S | No | Yes | 43.74 | 1,000 | 43.74 k | 2,097 |
2 Jan 24 | Woltosz Walter S | Common Stock | Sell | Dispose S | No | Yes | 44.88 | 464 | 20.82 k | 3,659,403 |
2 Jan 24 | Woltosz Walter S | Common Stock | Sell | Dispose S | No | Yes | 44.45 | 19,536 | 868.38 k | 3,659,867 |
News
Simulations Plus And University Of Bath Awarded FDA Grant
5 Mar 24
Simulations Plus Extends Collaboration With Translational Toxicology Division At National Institute Of Environmental Health Sciences For Rapid Safety Assessment Of Chemicals In Animals And Humans
15 Feb 24
Simulations Plus Nurtures Growth and Provides Investors with Value.
5 Feb 24
Simulations Plus: Dividend Insights
23 Jan 24
Simulations Plus Embarks On Collaboration With Northeastern University And The TIM Company Through New FDA Grant
9 Jan 24
Press releases
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
20 Mar 24
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
13 Mar 24
Simulations Plus and the University of Bath Awarded New FDA Grant
5 Mar 24
Simulations Plus Launches Corporate Development Initiative
13 Feb 24
Simulations Plus to Participate in Upcoming Healthcare Conferences
6 Feb 24